TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Normal skin flora CFU count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of pathogens identified
Endpoint domain: Adverse events/effects
Primary endpoint: Symptoms of infection
Endpoint domain: Adverse events/effects
Primary endpoint: Self-care activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic control variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: UVB skin thermal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: HBV DNA loss rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healing of ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h IOP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean plasma concentrations of BDNF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean plasma concentrations of TARC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nasal discomfort score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apoptotic index in stromal layers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean plasma baloxavir acid concentration 24 h after single-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic Blood Pressure (BP) readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic Blood Pressure (BP) readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Engagement in unhealthy weight loss behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum drug concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of cold shivers
Endpoint domain: Adverse events/effects
Primary endpoint: Control over nocturnal eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instances of nocturnal eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tiredness reported during nocturnal eating episodes
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Blood prolactin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: High-density lipoprotein cholesterol levels decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Child ratings of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting plasma PYY concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutrient-stimulated plasma PYY concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma CCK concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Dietary Risk Assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood cholesterol reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cobb's angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of viral infection
Endpoint domain: Adverse events/effects
Primary endpoint: Inhibitor development
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy in coping with depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severe negative outcomes of depression
Endpoint domain: Adverse events/effects
Primary endpoint: remineralisation of non‐cavitated occlusal white spot lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Number of days with migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Working disability
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Postoperative glare under mesopic conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual complaint score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hematological acute morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Mean maximum detrusor pressure at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of medication use-related problems
Endpoint domain: Adverse events/effects
Primary endpoint: Prolonged third stage of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Postpartum hemorrhage (PPH)
Endpoint domain: Adverse events/effects
Primary endpoint: Ten-Meter Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSI score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: melanin index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of deep sternal wound infections
Endpoint domain: Adverse events/effects
Primary endpoint: muscle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's overall assessment of disease activity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of head shadow effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QuickSIN scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation rates in vaccine trials
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: V(O(2) )max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean HRSD scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biased tag selection
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: blog post selection
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: treatment efficacy ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete healing of ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of ulcers by more than 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: case detection of tuberculosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean time in POAF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Irritable bowel syndrome symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quality of life (general health perception)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of doctor visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Erythropoietin (EPO) response to anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain intensity at the site of propofol injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palatal height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palatal width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to complex medication regimens
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PSA50 rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: cessation rate of exclusive breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of non-CMV disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rates of CMV disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: continued physical IPV
Endpoint domain: Adverse events/effects
Primary endpoint: continued sexual IPV
Endpoint domain: Adverse events/effects
Primary endpoint: continued emotional aggression
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of procedural difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient pain score
Endpoint domain: Adverse events/effects
Primary endpoint: Behavioural intentions to use sunscreen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Global small bowel motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: median renal clearance of ciprofloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: median renal clearance of M1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Decline of motor functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Pain Score (PPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal periostin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: body temperature maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shivering incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Vocal cord visibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of neuromuscular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean probing attachment levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of iron deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of microcytosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ergometric test pain-free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systemic reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Immune response (titers post boost)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 2-hour plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Constant scores 12 months postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAER latencies for wave V
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BAER latencies for wave III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BAER latencies for wave I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Delayed word recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Surgeons' performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Undetectable plasma HIV‐1 RNA levels at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median change from baseline in CD4+ cell count at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Costs of therapies
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduced surgical time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Size of the bone flap
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Aesthetic results
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence to medication regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival without myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: angiographic disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pathological RV measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prolonged DT measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prolonged VT measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: TgAb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: TPOAb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of Hashimoto's thyroiditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Success rate at 24 and 48 months
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of superficial punctate keratitis
Endpoint domain: Adverse events/effects
Primary endpoint: Hospital admission rate at 6 months
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Maximal concentration of ALA in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximal concentration of DHA in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: levodopa maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration‐time curve from 0 to 3 hours (AUC0‐3 hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough FEV1 after 14 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-treatment drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rebound withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recrudescence rate of H. pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ulcer relapse rate in patients with recrudescent infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean percentage of weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of participants losing ≥5% of re-randomization weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maintenance of full weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total DNA count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of strokes
Endpoint domain: Adverse events/effects
Primary endpoint: Paravalvular regurgitation
Endpoint domain: Adverse events/effects
Primary endpoint: Serum interleukin-6 (IL-6) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival rate of RMGIC restorations
Endpoint domain: Mortality/survival
Primary endpoint: Total annual healthcare costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: total weekly average community CSD sales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vowel and monosyllabic word discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech perception tests performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sound quality preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of postherpetic neuralgia (PHN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of postherpetic neuralgia (PHN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in SiSBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients who responded (SiSBP <140 mm Hg or a >=20-mm Hg decrease in SiSBP from baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of drug-related CAEs
Endpoint domain: Adverse events/effects
Primary endpoint: IFN-gamma production levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants losing > 5% of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter observer reliability of long axis measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra observer reliability of long axis measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean improvement in vertigo symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival without neurological or developmental abnormalities
Endpoint domain: Mortality/survival
Primary endpoint: Gait Speed Change (GS-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of PAC responders at 42 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of MCID responders at 42 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Psychomotor Development Index (PDI)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mental Development Index (MDI)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: shank/rearfoot coupling variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 24-h intragastric pH >4 maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Twenty-four hour morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygenation following extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variceal recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage of total energy from energy-dense, nutrient-poor foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percentage of energy from nutrient-dense foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Patients with Controlled Ambulatory BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Morning BP Surge Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HIV RNA copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in mean monthly migraine frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in severity of migraine attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in average duration of migraine attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CST atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: baseline motor arm function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement for vascular lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain ratings
Endpoint domain: Adverse events/effects
Primary endpoint: Coronary vascular resistance (CVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognitive outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: reduced lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Volume of lymphoedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Absence of clinical implant mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of bone resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemically validated abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in erectile dysfunction status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: increase in exercise treadmill time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes